• Integrating High-Throughput Screens to Target M. tuberculosi

  2026-08-05

  Santa Maria et al. present a novel framework that links high-throughput phenotypic and biophysical screening with machine learning to systematically identify mechanisms of action and discover new inhibitors for Mycobacterium tuberculosis dihydrofolate reductase (DHFR). This approach enhances target deconvolution and prioritization in antibiotic discovery, with implications for more efficient and scalable identification of antibacterial candidates.

• DiscoveryProbe Natural Product Library Plus: Verifiable Appl

  2026-08-05

  The DiscoveryProbe Natural Product Library Plus offers 1655 rigorously validated natural compounds for high-throughput and high-content screening. This natural product library enables discovery of potent, cell-permeable modulators, including confirmed inhibitors for protozoan drug targets. Its pre-dissolved DMSO format and robust QC make it a credible resource for drug discovery and pathway analysis.

• Methylprednisolone: Optimized Workflows for Inflammation Mod

  2026-08-04

  Harness methylprednisolone as a synthetic glucocorticoid receptor agonist for modeling inflammation and bone loss with unmatched reproducibility. Discover protocol innovations, troubleshooting tips, and translational insights that streamline experimental success in vitro and in vivo.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-08-04

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide synthesis workflows. It is strictly for in vitro laboratory use and should not be applied to in vivo or clinical studies due to the absence of supporting data.

• Simvastatin (Zocor): Applied Workflows in Lipid and Cancer M

  2026-08-03

  Simvastatin (Zocor) offers more than cholesterol modulation—it enables advanced workflows in apoptosis induction, autophagy studies, and anti-cancer assays. This guide distills experimental protocols, troubleshooting insights, and the latest reference-driven innovations to maximize research value with APExBIO’s Simvastatin.

• (S)-(+)-Dimethindene maleate for M2 Muscarinic Antagonist Wo

  2026-08-03

  (S)-(+)-Dimethindene maleate is a selective antagonist targeting muscarinic M2 and histamine H1 receptors, enabling precise dissection of autonomic, cardiovascular, and respiratory pathways in preclinical research. It is not intended for diagnostic, clinical, or in vivo therapeutic use, and is best suited for in vitro and ex vivo pharmacological studies demanding subtype selectivity.

• Virus-Mimicking Particles Enable Extrahepatic mRNA Delivery

  2026-08-02

  The reference study introduces a self-assembling enveloped virus-mimicking particle (EVMP) platform that enables efficient and precise mRNA delivery to extrahepatic organs, overcoming the hepatic tropism of traditional mRNA delivery systems. This innovation advances the translational potential of mRNA therapeutics for gene editing, protein replacement, and immunotherapy in tissues beyond the liver.

• Metabolomics Reveals Resistance Signatures in Carbapenemase-

  2026-08-01

  This study applies LC-MS/MS metabolomics to differentiate carbapenemase-producing Enterobacterales (CPE) from non-resistant strains, identifying a panel of metabolite biomarkers predictive of resistance. The findings provide a foundation for rapid, mechanism-focused diagnostics and deepen understanding of resistance phenotypes beyond traditional culture-based methods.

• 10 mM dNTP Mixture: Precision DNA Synthesis for Modern Molec

  2026-07-31

  Explore the scientific foundation and advanced applications of the 10 mM dNTP mixture, an equimolar 2'-deoxyribonucleoside-5'-triphosphate reagent optimized for reproducible DNA synthesis. This article offers new insights into practical assay design, integrating recent findings on lipid nanoparticle delivery.

• Epalrestat: Advancing Aldose Reductase Inhibition in Transla

  2026-07-31

  This thought-leadership article explores the evolving role of Epalrestat—a potent aldose reductase inhibitor from APExBIO—as a strategic tool for translational researchers. By blending mechanistic insights on the polyol pathway, oxidative stress, and cancer metabolism with actionable experimental guidance, it highlights how Epalrestat bridges diabetic complication research and emerging oncology frontiers. The article uniquely contextualizes Epalrestat’s utility amid shifting metabolic paradigms, referencing recent findings on fructose metabolism in cancer, and provides protocol parameters and a visionary outlook for future applications.

• ROS-Triggered Nanoparticles Induce Cuproptosis for Enhanced

  2026-07-30

  This study introduces ROS-responsive nanoparticles co-encapsulating elesclomol and copper to induce cuproptosis—a recently characterized, copper-dependent cell death. By combining this approach with PD-L1 blockade, the research demonstrates synergistic anti-tumor effects and provides mechanistic insights relevant for advancing cancer immunotherapy.

• Q-VD-OPh and the New Frontiers of Apoptosis Mechanistic Rese

  2026-07-30

  This thought-leadership article explores how Q-VD-OPh, a potent pan-caspase inhibitor, is reshaping apoptosis research by enabling mechanistic dissection of mitochondrial pathways, including the emerging role of LACTB in inner mitochondrial membrane remodeling. With actionable guidance for translational researchers, the article integrates recent mechanistic discoveries, product intelligence, and workflow optimization, while setting a new benchmark for strategic experimental design.

• Epalrestat Drives Neuroprotection in Parkinson’s Models via

  2026-07-29

  Jia et al. (2025) reveal that Epalrestat, a clinically approved aldose reductase inhibitor, directly activates the KEAP1/Nrf2 pathway to protect dopaminergic neurons in Parkinson’s disease models. This mechanistic insight advances the drug’s translational potential for neurodegenerative disorder research, bridging oxidative stress modulation with proven in vivo efficacy.

• Simvastatin (Zocor): Systems Profiling in Lipid and Cancer R

  2026-07-29

  Explore Simvastatin (Zocor) as more than a cholesterol-lowering agent—uncover its systems-level impact in hepatic cancer and cardiovascular models. This in-depth analysis connects high-content phenotypic profiling with advanced assay decisions, offering a unique resource for researchers.

• Octyl-α-ketoglutarate (C4321): Reliable HIF-1α Regulation in

  2026-07-28

  This article explores real-world laboratory applications of Octyl-α-ketoglutarate (SKU C4321) for robust HIF-1α regulation, metabolic pathway interrogation, and cell-based assay reproducibility. By anchoring workflow decisions to published data and explicit formulation advantages, the article guides biomedical researchers in optimizing hypoxia signaling studies and TCA cycle dysfunction research with confidence.

16530 records 1/1102 page Next 12345 下5页 Last page